Arca Biopharma’s board has approved a reverse stock split ahead of its anticipated merger with Oruka. The decision is seen as a strategic maneuver aimed at optimizing the company’s stock structure before the merger process. The merger with Oruka promises to combine strengths and enhance competitiveness in the biotechnology sector. The move indicates Arca Biopharma’s commitment to maximizing shareholder value while setting the stage for a smooth merger transition.
Biotechnology, Financial Services,United States
https://mergersacquisitions.einnews.com/article/738433019/KdakA7ZH13h2ze2e?ref=rss&ecode=Q1vNcweEggLWKz7L